Real-World experience of tyrosine kinase inhibitors in children and adults patients with recurrent bone tumours

Principle Investigator
Abha Gupta
Date Approved
December 23, 2021
Patients with recurrent Ewing sarcoma, Chondrosarcoma or Osteosarcoma have very few treatment options. Recently, 2 trials have described the benefit of Regorafenib and Cabozantinib in both diseases. We report the real-world Canadian experience of these drugs for children and adults with relapsed bone tumours.
View All Active Projects